gene

ADRA2A

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ADRA2A: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

241Connections

1Hypotheses

1Analyses

50Outgoing

50Incoming

10Experiments

1Debates

No summary available yet. View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	ADRA2A
Target Class	Gpcr
Function	is an important component in the neurobiology of neurodegenerative diseases.
Mechanism of Action	Small molecule agonists and antagonists modulating noradrenergic signaling
Druggability	Medium (0.59)
Clinical Stage	Approved
GeneCards	ADRA2A
Human Protein Atlas	ADRA2A
Associated Diseases	Als, Alzheimer, Alzheimer's disease, anxiety
Known Drugs/Compounds	mirtazapine
Interactions	ADRA1A, ADRA2B, ADRB1, ALDH1A2, CTSD, DBH
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	Noradrenergic-Tau Propagation Blockade
KG Connections	238 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

ADRA2A Gene

gene · 645 words

→

Pathway Diagram

graph TD
    ADRA2A["ADRA2A Gene
(alpha2A-Adrenergic Receptor)"]
    
    NE["Norepinephrine
Neurotransmitter"]
    SYN["Synaptic
Transmission"]
    
    SLC6A2["SLC6A2
(Norepinephrine Transporter)"]
    COMT["COMT
(Catechol-O-Methyltransferase)"]
    
    ALZHEIMER["Alzheimer's
Disease"]
    DEMENTIA["Dementia"]
    DEPRESSION["Depression"]
    ALS["Amyotrophic
Lateral Sclerosis"]
    
    CHAT["CHAT
(Choline Acetyltransferase)"]
    ACH["Acetylcholine
System"]
    
    EPIGEN["Epigenetic
Regulation"]
    THER["Therapeutic
Intervention"]
    
    NE -->|"binds to"| ADRA2A
    ADRA2A -->|"inhibits"| SYN
    ADRA2A -->|"regulates"| NE
    
    SLC6A2 -->|"reuptakes"| NE
    COMT -->|"degrades"| NE
    
    ADRA2A -->|"associated with"| ALZHEIMER
    ADRA2A -->|"therapeutic target"| DEMENTIA
    ADRA2A -->|"associated with"| DEPRESSION
    ADRA2A -->|"associated with"| ALS
    
    CHAT -->|"produces"| ACH
    ADRA2A -->|"interacts with"| CHAT
    ACH -->|"cognitive function"| ALZHEIMER
    
    EPIGEN -->|"regulates"| ADRA2A
    ADRA2A -->|"target for"| THER
    
    style ADRA2A fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
    style THER fill:#1b5e20,stroke:#66bb6a,stroke-width:2px
    style EPIGEN fill:#1b5e20,stroke:#66bb6a,stroke-width:2px
    style ALZHEIMER fill:#7d4200,stroke:#ff9800,stroke-width:2px
    style DEMENTIA fill:#7d4200,stroke:#ff9800,stroke-width:2px
    style DEPRESSION fill:#7d4200,stroke:#ff9800,stroke-width:2px
    style ALS fill:#7d4200,stroke:#ff9800,stroke-width:2px
    style SLC6A2 fill:#4a1a6b,stroke:#ba68c8,stroke-width:2px
    style COMT fill:#4a1a6b,stroke:#ba68c8,stroke-width:2px
    style CHAT fill:#4a1a6b,stroke:#ba68c8,stroke-width:2px

Outgoing (183)

Target	Relation	Type	Str
benchmark_ot_ad_answer_key:ADRA2A	data_in	dataset_row	0.00
benchmark_ot_ad_answer_key:ADRA2A	data_in	dataset_row	0.00
ds-83b31ef18d49	provides_data_for	dataset	1.00
Mirtazapine	associated_with	drug	0.95
noradrenergic signaling	involved_in	pathway	0.90
semen quality	regulates	phenotype	0.80
Semen Quality	regulates	phenotype	0.80
MAPT	regulates_propagation	gene	0.80
Human Height	associated_with	phenotype	0.75
male fertility	contributes_to	phenotype	0.75
Ovarian Cancer	therapeutic_target	disease	0.75
SLC30A8	associated_with	gene	0.70
Ovarian Cancer	associated_with	disease	0.70
Anxiety	associated_with	disease	0.65
Type 2 Diabetes	associated_with	disease	0.65
Dementia	therapeutic_target	disease	0.65
Als	associated_with	disease	0.65
Depression	associated_with	disease	0.65
Alzheimer	associated_with	disease	0.65
Dementia	interacts_with	disease	0.65
Diabetes	associated_with	disease	0.65
Dementia	associated_with	disease	0.65
GABRA1	associated_with	gene	0.60
APOE	associated_with	gene	0.60
CYP2D6	associated_with	gene	0.60
HTR2C	associated_with	gene	0.60
NBEA	associated_with	gene	0.60
Rb	associated_with	protein	0.60
DNMT3B	expressed_in	gene	0.60
DNMT1	expressed_in	gene	0.60
DNMT3A	expressed_in	gene	0.60
PI3K	expressed_in	gene	0.60
ADRA2B	expressed_in	gene	0.60
MBD2	expressed_in	gene	0.60
AKT	expressed_in	gene	0.60
MAPK14	associated_with	gene	0.60
COMT	associated_with	gene	0.60
CHAT	associated_with	gene	0.60
HMGCR	associated_with	gene	0.60
OPRM1	associated_with	gene	0.60
MAOB	associated_with	gene	0.60
MAOA	activates	gene	0.60
RPN2	activates	gene	0.60
MAOA	causes	gene	0.60
RPN2	causes	gene	0.60
cancer	causes	disease	0.60
Epigenetic	associated_with	pathway	0.60
Alzheimer's disease	associated_with	disease	0.60
autophagy pathway	participates_in	pathway	0.60
unfolded protein response	participates_in	pathway	0.60

Incoming (58)

Source	Relation	Type	Str
benchmark_ot_ad_answer_key:ADRA2A	data_in	dataset_row	0.00
benchmark_ot_ad_answer_key:ADRA2A	data_in	dataset_row	0.00
ds-83b31ef18d49	data_in	dataset	1.00
NECL1	regulates	gene	0.95
mirtazapine	targets	drug	0.90
h-4113b0e8	targets_gene	hypothesis	0.90
NECL1 deficiency	upregulates	phenotype	0.85
h-4113b0e8	targets	hypothesis	0.80
BCHE	associated_with	gene	0.60
ADRA1A	interacts_with	gene	0.60
ABCB1	modulates	gene	0.60
CYP3A5	associated_with	gene	0.60
PER	therapeutic_target	gene	0.60
CYP1A2	associated_with	gene	0.60
GSTP1	associated_with	gene	0.60
CYP3A4	associated_with	gene	0.60
ADRB2	associated_with	gene	0.60
SLC6A2	associated_with	gene	0.60
SLC6A4	associated_with	gene	0.60
ABCG2	associated_with	gene	0.60
DEPRESSION	associated_with	gene	0.60
PER	interacts_with	gene	0.60
CYP2E1	associated_with	gene	0.60
ALZHEIMER	associated_with	gene	0.60
ALZHEIMER'S DISEASE	associated_with	gene	0.60
ANXIETY	associated_with	gene	0.60
GENES	interacts_with	gene	0.60
MAOB	associated_with	gene	0.60
GABRA1	associated_with	gene	0.60
CHAT	associated_with	gene	0.60
CYP2D6	associated_with	gene	0.60
APOE	associated_with	gene	0.60
HMGCR	associated_with	gene	0.60
OPRM1	associated_with	gene	0.60
SLC30A8	associated_with	gene	0.60
COMT	associated_with	gene	0.60
NBEA	associated_with	gene	0.60
HTR2C	associated_with	gene	0.60
ABCB1	associated_with	gene	0.60
SLC6A3	associated_with	gene	0.60
ADRA1A	co_expressed_with	gene	0.50
ADORA2A	debate_co_mention	gene	0.45
Guanfacine NorAD - Phase 3 Trial for Alzheimer's Disease	references	clinical	0.40
ABCB1	co_mentioned	gene	0.40
adra2b Protein	references	protein	0.40
CLOCK	co_discussed	gene	0.40
BDNF	co_discussed	gene	0.40
AQP4	co_discussed	gene	0.40
MTNR1A	co_discussed	gene	0.40
CX3CR1	co_discussed	gene	0.40

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Noradrenergic-Tau Propagation Blockade	0.711	neurodegeneration	Sleep disruption as cause and consequenc

Mentioning Analyses (1)

Scientific analyses that reference this entity

Sleep disruption as cause and consequence of neurodegeneration

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.763

Experiments (10)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
s:** - Compare tau strain spreading in EXT1/EXT2 conditional knockout	falsification	Neurodegeneration	0.400	0.50	mouse	proposed	$260,000
4R-Tau Targeting Therapies for PSP and CBS	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$6,550,000
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation and Neuro	exploratory	Parkinson's Disease	0.400	0.50	human	proposed	$2,070,000
Anti-Tau Immunotherapy Dosing Optimization	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
Blood Biomarker vs Tau PET for Treatment Monitoring	clinical	ALS	0.400	0.50	human	proposed	$5,460,000
Combination Therapy Sequencing in Parkinson's Disease	validation	Parkinson's Disease	0.400	0.50	human	proposed	$2,280,000
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propagation Map	validation	Parkinson's Disease	0.400	0.50	cell_line	proposed	$160,000
Tau Co-Pathology in DLB Clinical Heterogeneity	clinical	Neurodegeneration	0.400	0.50	human	proposed	$5,460,000
Levodopa Response Determinants in PSP — Biomarker-Guided Prediction St	clinical	Neurodegeneration	0.400	0.50	human	proposed	$5,460,000
Experiment: Multi-Ethnic PD GWAS	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,500,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 po [PMID:31227597]	Snyder AG, Hubbard NW, Messmer MN, Kofma	Sci Immunol	2019	1
Effect of etching with potassium hydrogen difluoride and ammonium hydrogen diflu [PMID:31068549]	Akazawa N, Koizumi H, Nogawa H, Kodaira	Dent Mater J	2019	1
Synapse formation in the brain can be enhanced by co-administering three specifi [PMID:29031899]	Wurtman RJ	Eur J Pharmacol	2017	1
Engineered AAVs for efficient noninvasive gene delivery to the central and perip [PMID:28671695]	Chan KY, Jang MJ, Yoo BB, Greenbaum A, R	Nat Neurosci	2017	1
The Pediatric Imaging, Neurocognition, and Genetics (PING) Data Repository. [PMID:25937488]	Jernigan TL, Brown TT, Hagler DJ Jr, Aks	Neuroimage	2016	1
Regulation of Lipid Biology-Associated Gene Expression in Granulosa Cells in Hyp [PMID:41605187]	["Berkel C"]	Lipids	2026	0
Meta-GWAS of Pig Semen Quality Traits Reveals Conserved Genes Regulating Mammali [PMID:41504393]	["Lin Q", "Cai X", "Zhong Z", "Li T", "C	Advanced science (Weinheim, Ba	2026	0
Necl1 deficiency induces noradrenergic dysfunction and depressive-like states in [PMID:41308882]	["Song J", "Wang L", "Suo J", "Ran K", "	Journal of affective disorders	2026	0
The contribution of phenolic endocrine-disrupting chemicals to breast cancer ris [PMID:41673191]	["Dou Y", "Li X", "Li M", "Shang J", "Xu	Scientific reports	2026	0
Transcriptomics reveals new therapeutic targets for ovarian cancer. [PMID:41577183]	["Feng Y", "Liu G"]	SLAS technology	2026	0
Noradrenergic inhibition of definitive POMC neurons through direct and indirect [PMID:41877438]	Lavoie O, Turmel A, Khouma A, Minbashi M	Journal of neuroendocrinology	2026	0
The Neuroimmunome of Hepatitis Patients Associates With Disease Severity. [PMID:41347690]	["N\u00f3bile A", "Adri A", "Usuda J", "	Journal of medical virology	2025	0
Neuro-Mesenchymal Interaction Mediated by a β2-Adrenergic Nerve Growth Factor Fe [PMID:39137067]	["Kobayashi H", "Iida T", "Ochiai Y", "M	Cancer discovery	2025	0
Molecular Profiling of Genes Associated With Methylphenidate Pathway Therapy and [PMID:41058112]	["Santos A", "de Souza T", "Aguiar K", "	American journal of medical ge	2025	0
Probiotic Bactolac alleviates depression-like behaviors by modulating BDNF, NLRP [PMID:40281288]	["I\u015f\u0131k M", "K\u00f6se F", "Bud	Pflugers Archiv : European jou	2025	0
Promising Antidepressant Potential: The Role of Lactobacillus rhamnosus GG in Me [PMID:39962033]	["I\u015f\u0131k M", "K\u00f6se F", "\u0	Probiotics and antimicrobial p	2025	0
Unveiling the molecular mechanisms of human platelet lysate in enhancing endomet [PMID:40663777]	["Nguyen T", "Kwok Y", "Zhang C", "Russe	Human reproduction (Oxford, En	2025	0
Sympathetic nerve-enteroendocrine L cell communication modulates GLP-1 release, [PMID:38242116]	["Ren W", "Chen J", "Wang W", "Li Q", "Y	Neuron	2024	0
Enterococcus-derived tyramine hijacks α [PMID:38788722]	["Li C", "Zhang P", "Xie Y", "Wang S", "	Cell host & microbe	2024	0
Tumour immune rejection triggered by activation of α2-adrenergic receptors. [PMID:37286594]	Zhu J, Naulaerts S, Boudhan L, Martin M,	Nature	2023	0

Debates (1)

Multi-agent debates referencing this entity

Sleep disruption as cause and consequence of neurodegeneration

closed · Rounds: 4 · Score: 0.91 · 2026-04-06